17
Sep

Just months after pulling off a successful IPO, Flexion Therapeutics is left watching its shares plummet after the FDA forced it to halt a trial on its top prospect.

…read more

Source: Flexion tanks as FDA clamps a hold on its lead osteoarthritis drug

    

0 No comments